PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios

Akari Therapeutics, Plc (AKTX)

Equity · Currency in USD · Last updated Oct 3, 2023
SummaryFinancials

Company Info

ISINUS00972G1085
CUSIP00972G108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$19.97M
EPS-$5.55
EBITDA (TTM)-$21.23M
Year Range$2.81 - $13.40
Target Price$55.00
Short %0.19%
Short Ratio0.49

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Akari Therapeutics, Plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%MayJuneJulyAugustSeptemberOctober
-12.50%
4.84%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AKTX

Akari Therapeutics, Plc

Return

Akari Therapeutics, Plc had a return of -61.56% year-to-date (YTD) and -71.51% in the last 12 months. Over the past 10 years, Akari Therapeutics, Plc had an annualized return of -52.32%, while the S&P 500 had an annualized return of 10.00%, indicating that Akari Therapeutics, Plc did not perform as well as the benchmark.


PeriodReturnBenchmark
1 month8.15%-5.04%
6 months-9.51%4.58%
Year-To-Date-61.56%11.69%
1 year-71.51%16.58%
5 years (annualized)-39.41%8.16%
10 years (annualized)-52.32%10.00%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-47.33%-0.33%-2.32%-3.90%46.82%-36.90%25.40%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AKTX
Akari Therapeutics, Plc
-0.76
^GSPC
S&P 500
1.04

Sharpe Ratio

The current Akari Therapeutics, Plc Sharpe ratio is -0.76. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00MayJuneJulyAugustSeptemberOctober
-0.76
1.04
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Dividend History


Akari Therapeutics, Plc doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%MayJuneJulyAugustSeptemberOctober
-99.93%
-10.59%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Akari Therapeutics, Plc is 99.94%, recorded on Mar 30, 2023. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.94%May 23, 20132261Mar 30, 2023

Volatility Chart

The current Akari Therapeutics, Plc volatility is 23.31%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%MayJuneJulyAugustSeptemberOctober
23.31%
3.15%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)